Journal
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume 64, Issue 4, Pages 647-655Publisher
SPRINGER
DOI: 10.1007/s00280-009-1050-5
Keywords
Temozolomide; Brain tumor; Alkylating chemotherapy; Malignant glioma; Glioblastoma; Tumor resistance
Categories
Ask authors/readers for more resources
Temozolomide (TMZ) is an oral alkylating agent that is regarded as a tolerable and effective drug. When combined with radiotherapy in patients with newly diagnosed glioblastoma, survival is significantly prolonged. This finding has led to widespread use of TMZ for patients with this disease. We summarize developing concerns regarding the use of TMZ, imaging of malignant gliomas, and the pharmacology of TMZ-mechanism of action, scheduling and strategies for overcoming resistance.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
